Endoscopic screening for gastrointestinal cancers

Precise estimates of the magnitude of benefits and harms of endoscopic screening for cancer are a prerequisite for informed decision making for or against participation in screening for individuals in the target population.

Photo: Colourbox

In the paper Do’s and don’ts in evaluation of endoscopic screening for gastrointestinal cancers published online first in the journal Endoscopy on Sept 21st, Michael Bretthauer and co-workers from the Clinical Effectiveness Research group outline the most common pitfalls in the evaluation of screening and offer recommendations for future studies.

Latest publications

Smeby et al. 2020. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine 59: 102923 Eilertsen et al. 2020. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Lett. 469: 246-255 Araghi et al. 2020. Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut gutjnl-2020-320625 Lopes et al. 2020. A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis. Gastric Cancer 23: 811-823 Bruun et al. 2020. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Clin. Cancer Res. 26: 4107-4119 All publications